Azitra (AZTR) Q1 2025 earnings summary

Executive summary

• Focused on developing precision dermatology therapies using engineered proteins and live biotherapeutic products, leveraging a proprietary microbial library and AI/ML technology for candidate selection.

• Lead programs include ATR-12 for Netherton syndrome (Phase 1b ongoing) and ATR-04 for EGFR inhibitor-associated rash (IND cleared, Fast Track), both progressing through early-stage trials.

• ATR-01 for ichthyosis vulgaris is in IND-enabling studies planned for 2025.

• No commercial revenue; operations funded by equity offerings and a $20 million equity purchase agreement with Alumni Capital LP.

• Presented ATR-04 Phase 1/2 trial data at ASCO 2025, highlighting innovation in dermatology therapeutics.

Financial highlights

• Net loss for Q1 2025 was $3.1 million, a 5% increase year-over-year.

• Total operating expenses rose 5% to $3.1 million, with general and administrative costs up 24% to $1.9 million and R&D expenses down 15% to $1.3 million.

• Cash and cash equivalents at March 31, 2025 were $3.2 million; working capital was $2.6 million.

• Net cash used in operating activities was $3.07 million; financing activities provided $1.75 million in Q1 2025.

• Total assets as of March 31, 2025: $5.9 million; total liabilities: $1.5 million; stockholders' equity: $4.4 million.

Outlook and guidance

• Cash on hand is not sufficient to fund operations for the next twelve months; additional capital will be required.

• Management has substantial doubt about the ability to continue as a going concern without further financing.

• Plans to seek additional funds through equity/debt offerings, grants, licensing, or partnerships.

• Initial safety data for ATR-12 Phase 1b in Netherton syndrome expected in 1H 2025, with topline results by year-end.

• First patient dosing for ATR-04 Phase 1/2 trial anticipated by mid-2025; multiple clinical updates expected in 2025.